Answers are grounded in this paper and cite their sources.
To determine the impact of CYP3A inhibition on the clearance of a CYP3A substrate in vivo, ketoconzole (KTZ) has been widely used as a strong reversible inhibitor. The draft FDA drug interaction guidance published in 2006 recommended that when KTZ is used as a CYP3A inhibitor, it should be administered as 400 mg once daily for several days.1,2 Oo et al had questioned the need of multiple doses of 400 mg of KTZ as a precipitant inhibitor of a CYP3A substrate and proposed that a single 400-mg KTZ dose be considered.3 The reasons behind their suggestion included (1) KTZ has a short half-life (t1/2 ∼3–5 hours) and accumulation is not expected after multiple-dose administration and that (2) even with a recent study4 showed that predosing of KTZ resulted in 36% increase in midazolam AUC ratio (day 5 over day 1), the increase is predictable.5 We thank the authors for sharing their insights.3 The authors were correct in that if the CYP3A substrate being studied shares certain pharmacokinetic characteristics with midazolam (eg, short t1/2 and low percentage bioavailability [F]), then a single 400-mg KTZ would be sufficient. We have recently performed in silico simulations to evaluate the impact of various KTZ dosing regimens on the AUC changes of CYP3A substrates with various pharmacokinetic characteristics. Our simulation results6 suggested that a single KTZ 400-mg dose will provide maximal inhibition for only a subset of substrates that have low F and short t1/2 values, including midazolam. For example, in figure 1 of the article by Zhao et al,6 substrates with a t1/2 = 2.7 hours and F = 0.2, the AUC ratios (AUC with KTZ vs AUC without KTZ) after multiple doses and a single dose were 18.4 and 17.5, respectively (with the ratio after multiple doses over single dose close to unity: 1.00–1.05 for substrates with t1/2 <2.7 hours and F of <0.2). However, for substrates with a t1/2 longer than that of KTZ, multiple dosing of KTZ is critical. For example (figure 1 of Zhao et al6), for substrates with a t1/2 of 21 hours and F of 0.88, the AUC ratios after multiple doses and a single dose were 3.3 and 1.7, respectively (with the ratio after multiple doses over single dose of 2.0). In addition, for these substrates, the twice-daily dosing regimen (200 mg twice daily, total daily dose of 400 mg) appeared to provide a higher degree of inhibition than the once-daily 400-mg dosing regimen by providing more sustained CYP3A inhibition (ratio of twice daily over once daily of 1.6). Our simulation results also indicated that the timing of coadministration of a quickly absorbed CYP3A substrate relative to that of KTZ can be critical, especially if the substrate is to be coadministered with a single dose KTZ, in which the maximum inhibition of intestinal/liver CYP3A prior to the absorption of the substrate is crucial. It is thus important to recognize that there is not a single optimal design for drug interaction evaluation: one must consider the pharmacokinetic characteristics of both substrates and inhibitors when designing in vivo drug interaction studies. We encourage the study sponsors to use modeling and simulation to determine the best dosing strategy.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: